Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors
July 24 2020 - 7:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company
developing treatments for rare and specialty diseases with
significant unmet needs, today announced the appointment of Barry
P. Flannelly, Pharm.D, to its Board of Directors. Dr. Flannelly,
who currently serves as Executive Vice President, General Manager,
North America, at Incyte, brings to Protara over 20 years of
commercial and business development leadership experience across
numerous leading pharmaceutical and biotech companies. Dr.
Flannelly will replace Scott Braunstein, M.D., who resigned
from the Board to focus on his role as Chief Executive Officer at
Marinus Pharmaceuticals.
“It is a pleasure to welcome Barry to our Board
of Directors at this exciting juncture for Protara as we continue
to advance our diverse pipeline of potentially transformative
therapies in multiple underserved areas,” said Jesse Shefferman,
Chief Executive Officer of Protara. “We look forward to leveraging
his vast commercial and operational expertise as we begin to lay
the groundwork for a potential path to market in the U.S. for our
lead program, TARA-002, for the treatment of lymphatic
malformations. I would also like to thank Scott for his
contributions and insights in helping to build Protara into the
company we are today and wish him well in all of his future
endeavors.”
“It has been a privilege to serve alongside the
talented Protara management team and my fellow Board members over
the past two years, a time during which the Company evolved
significantly into the exciting organization it is today with
multiple opportunities for growth,” said Dr. Braunstein. “I wish
the Company continued success in executing on its mission to
advance transformative therapies for people with rare and specialty
diseases.”
“Protara is a unique opportunity in the
biopharmaceutical landscape, with a promising portfolio,
experienced leadership team and multiple late-stage assets,” said
Dr. Flannelly. “I look forward to contributing to the Company’s
mission to become a leader in the rare and specialty disease
space.”
Dr. Flannelly joined Incyte as Executive Vice
President, Business Development and Strategic Planning, in August
2014 and was appointed General Manager, U.S., in June 2015. He
began his career in the pharmaceutical and biotech industry at
Rhone-Poulenc Rorer in 1997, which later became Sanofi-Aventis. Dr.
Flannelly has held roles of increasing responsibility in medical
affairs, strategic planning, and commercial operations at Novartis
Pharmaceuticals Corporation, Abraxis Oncology, Onyx
Pharmaceuticals, Inc., and Nektar Therapeutics. Throughout his
career, he has led the successful launch of several products in the
U.S. and worldwide for oncology indications including breast,
prostate, lung, and gastric cancers. Prior to joining the industry,
Dr. Flannelly served as Manager of Pharmacy Services at The Johns
Hopkins Oncology Center. He earned his Doctor of Pharmacy from the
University of Maryland School of Pharmacy, his Master’s in Business
Administration from the University of Baltimore, and his Bachelor
of Science in Pharmacy from Massachusetts College of Pharmacy.
About Protara Therapeutics,
Inc.
Protara is committed to identifying and
advancing transformative therapies for people with rare and
specialty diseases who have limited treatment options. Protara’s
portfolio includes its lead program, TARA-002, an investigational
cell-based therapy being developed for the treatment of lymphatic
malformations, and IV Choline Chloride, an investigational
phospholipid substrate replacement therapy for the treatment of
IFALD. For more information, visit www.protaratx.com
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding Protara’s business strategy, Dr. Flannelly’s
expected role on Protara’s Board of Directors, the contribution of
Dr. Flannelly’s experience in helping Protara achieve its strategic
objectives, and Protara’s development plans for its lead program,
TARA-002, and for IV Choline Chloride. Risks that contribute
to the uncertain nature of the forward-looking statements include:
uncertainties related to Protara’s development programs, including
the initiation and completion of non-clinical studies and clinical
trials and the timing of required filings with the FDA and other
regulatory agencies; uncertainties related to the actual impacts
and length of such impacts caused by the COVID-19 pandemic; having
to use cash in ways or on timing other than expected; and the
impact of market volatility on cash reserves. These and other risks
and uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Protara's filings and reports with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Protara undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Company Contact:
Blaine Davis Protara Therapeutics Blaine.Davis@protaratx.com
646-844-0337
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024